Therapy of Acute Myeloid Leukemia: Adapting to Change
The recent approval of multiple novel and targeted therapeutics offers new hope and increasingly effective treatment options for patients with acute myeloid leukemia (AML). Long awaited clinical progress includes the development and approval of molecularly targeted, small molecule, and combination treatment approaches. This session will focus on the clinical management of AML in this new era of precision medicine, summarizing available evidence and highlighting optimal strategies for treatment and management.
Dr. Catherine Smith will discuss clinical advances in the care of patients with FLT3 mutations. She will evaluate the recent FDA approvals and provide guidance for current treatment algorithms, review the status of key ongoing clinical trials, and emphasize key areas of ongoing translational research.
Dr. Courtney DiNardo will summarize the current treatment landscape of AML and discuss novel compounds under clinical development. She will review the importance of a comprehensive genomic assessment and consider available treatment strategies particularly for patients considered inappropriate or refractory to standard intensive therapies.
Dr. Sylvie Freeman will examine the available approaches and the clinical and translational implications of minimal residual disease (MRD) assessments in AML. She will review how to define MRD, how and when to assess for MRD, and whether MRD measurements should be used to drive treatment decisions.
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members